RxDoctor Payments Data

Kirby Parker, MD

Internal Medicine · Montgomery, ALNPI 1316031677

Payments from drug & device makers

$12,744in general payments, 2019–2025

Across 778 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$989
  • Lilly USA, LLC$977
  • Novo Nordisk$928
  • AstraZeneca$799
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$12,65999%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)103$1,437
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC60$1,090
Pfizer68$989
Lilly USA, LLC65$977
Novo Nordisk57$928
AstraZeneca46$799
Astellas Pharma US Inc35$680
GSK38$600
Merck29$408
Abbott22$407
Boehringer Ingelheim27$402
Sumitomo Pharma America, Inc.18$373
Amgen(2 entities)19$332
Amarin Pharma, Inc.16$288
Bayer14$269
Sanofi-aventis U.S. LLC16$259
Sunovion Pharmaceuticals Inc.12$200
Axsome Therapeutics, Inc.7$171
Esperion Therapeutics, Inc.10$168
IBSA Pharma Inc.9$151
Eisai Inc.9$149
Johnson & Johnson7$111
Arbor Pharmaceuticals, Inc.4$100
Exact Sciences6$94
Ironwood Pharmaceuticals, Inc6$92
Mylan Specialty L.p.6$91
Dexcom, Inc.4$76
Adlon Therapeutics L.p.4$67
Aytu Biopharma, Inc.5$65
Otsuka America Pharmaceutical, Inc.3$64
Biohaven Pharmaceutical Holding Company Ltd.3$61
Evoke Pharma, Inc.3$57
Phathom Pharmaceuticals, Inc.4$57
Assertio Therapeutics, Inc.4$55
Clarus Therapeutics Inc.3$55
E.r. Squibb & Sons, L.L.C.3$53
Ardelyx, Inc.2$46
Takeda Pharmaceuticals U.S.A., Inc.3$46
Teva Pharmaceuticals USA, Inc.3$45
Daiichi Sankyo Inc.2$35
Idorsia Pharmaceuticals US Inc2$35
Novartis2$34
Tolmar, Inc.2$32
Paratek Pharmaceuticals, Inc.2$32
Radius Health, Inc.1$28
Jazz Pharmaceuticals Inc.2$27
Genentech USA, Inc.2$27
Lundbeck LLC1$25
QOL Medical, LLC1$23
Boston Scientific1$21
Neurocrine Biosciences, Inc.1$20
Nestle Healthcare Nutrition Inc.1$20
Redhill Biopharma Inc.1$19
Tactile Systems Technology Inc1$17
Almatica Pharma LLC1$14
Impel Pharmaceuticals Inc.1$14
Kowa Pharmaceuticals America, Inc.1$12

How this compares

$12,744 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$117,973
Medicare patients
272
Services billed
2,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide168$178,869
OzempicSemaglutide140$143,606
JardianceEmpagliflozin121$131,891
Janumet XrSitagliptin Phos/Metformin Hcl117$114,633
EliquisApixaban105$95,186
RybelsusSemaglutide58$69,197
JanuviaSitagliptin Phosphate63$53,814
XareltoRivaroxaban46$50,607
GemtesaVibegron82$49,672
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$47,669
MyrbetriqMirabegron45$32,078
Xigduo XrDapaglifloz Propaned/Metformin38$30,948
BelsomraSuvorexant48$25,203
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$21,881
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$19,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$928$212,803198 claims
MerckJanumet Xr, Januvia, Belsomra, Janumet, Lagevrio (Eua)$408$208,402255 claims
Lilly USA, LLCMounjaro$977$178,869168 claims
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Tradjenta$402$162,086164 claims
PfizerEliquis$989$95,186105 claims
GSKTrelegy Ellipta, Anoro Ellipta$600$69,54998 claims
Johnson & JohnsonXarelto, Invokana$111$63,42762 claims
Sumitomo Pharma America, Inc.Gemtesa$373$49,67282 claims
Astellas Pharma US IncMyrbetriq$680$32,07845 claims
AstraZenecaFarxiga, Breztri Aerosphere$799$23,35228 claims
AbbVieLinzess, Synthroid$1,437$17,19773 claims
Sanofi-aventis U.S. LLCMultaq$259$9,41912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →